Interpace Diagnostics (IDXG) Misses Q1 EPS by 4c, Revenues Miss; Offers FY19 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
May 13, 2019 4:05 PM EDTQuarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year
Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase
Conference Call and Webcast Monday May 13, 2019 at 4:30 pm ET
Parsippany, NJ, May 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced financial results for the first quarter ended March 31, 2019, and reviewed recent business progress.
We had a strong start to the year highlighted by growth and driven by increasing volume in our... More
